

December 31, 2024

Annual Financial Statements and Other Information

AstraZeneca PLC ADRhedged™ (AZNH)

HSBC Holdings plc ADRhedged™ (HSBH)

Shell plc ADRhedged™ (SHEH)



Precidian ETFs Trust

Table of Contents

Schedule of Investments	
AstraZeneca PLC ADRhedged™	3
HSBC Holdings plc ADRhedged™	4
Shell plc ADRhedged™	5
Statements of Assets and Liabilities	6
Statements of Operations	7
Statements of Changes in Net Assets	8
Financial Highlights	9
Notes to Financial Statements.....	12
Report of Independent Registered Public Accounting Firm.....	21
Board Review of Investment Management Agreement	22

This report is provided for the general information of shareholders and is not authorized for distribution to prospective investors unless preceded or accompanied by a current prospectus.

AstraZeneca PLC ADRhedged™

Schedule of Investments

December 31, 2024

	<u>Shares</u>	<u>Value</u>
Common Stocks — 96.6%		
Health Care — 96.6%		
AstraZeneca PLC, ADR		
(Cost \$1,673,579).....	24,653	\$ 1,615,265
Short-Term Investment — 3.0%		
Money Market Funds — 3.0%		
Dreyfus Treasury Securities Cash Management Institutional Shares, 4.33% ^(a)		
(Cost \$49,645).....	49,645	49,645
Total Investments — 99.6%		
(Cost \$1,723,224)		1,664,910
Assets in excess of Other Liabilities, Net — 0.4%		<u>7,234</u>
Net Assets — 100%		<u>\$ 1,672,144</u>

(a) Reflects the 7-day yield at December 31, 2024.

ADR : American Depositary Receipt

PLC : Public Limited Company

At December 31, 2024, the Fund had the following currency swaps outstanding:

<u>Counterparty</u>	<u>Settlement Date*</u>	<u>Currency to Deliver</u>	<u>Currency to Receive</u>	<u>Unrealized Appreciation</u>	<u>Unrealized Depreciation</u>		
CIBC	01/02/25	USD	1,635,318	GBP	1,305,727	\$ —	\$ (31)
CIBC	01/02/25	GBP	1,305,727	USD	1,633,508	—	(1,779)
CIBC	01/03/25	GBP	1,290,747	USD	1,616,497	<u>14</u>	<u>—</u>
Total Unrealized Appreciation/(Depreciation)						<u>\$ 14</u>	<u>\$ (1,810)</u>

* The currency hedge contracts have an automatic extension on the maturity date, however the currency hedge contracts are marked to market and settled daily and the date reflected herein is the next settlement date.

Currency Abbreviations

USD U.S. Dollar

GBP Pound Sterling

HSBC Holdings plc ADRhedged™

Schedule of Investments

December 31, 2024

	<u>Shares</u>	<u>Value</u>
Common Stocks — 95.9%		
Financials — 95.9%		
HSBC Holdings plc, ADR		
(Cost \$1,545,070)	32,624	\$ 1,613,583
Short-Term Investment — 3.7%		
Money Market Funds — 3.7%		
Dreyfus Treasury Securities Cash Management Institutional Shares, 4.33% ^(a)		
(Cost \$62,054)	62,054	62,054
Total Investments — 99.6%		1,675,637
(Cost \$1,607,124)		
Assets in excess of Other Liabilities, Net — 0.4%		6,848
Net Assets — 100%		<u>\$ 1,682,485</u>

(a) Reflects the 7-day yield at December 31, 2024.

ADR : American Depositary Receipt

PLC : Public Limited Company

At December 31, 2024, the Fund had the following currency swaps outstanding:

<u>Counterparty</u>	<u>Settlement Date*</u>	<u>Currency to Deliver</u>	<u>Currency to Receive</u>	<u>Unrealized Appreciation</u>	<u>Unrealized Depreciation</u>		
CIBC	01/02/25	USD	1,609,818	GBP	1,285,367	\$ —	\$ (30)
CIBC	01/02/25	GBP	1,285,367	USD	1,608,037	—	(1,751)
CIBC	01/03/25	GBP	1,289,723	USD	1,615,214	14	—
Total Unrealized Appreciation/(Depreciation)						<u>\$ 14</u>	<u>\$ (1,781)</u>

* The currency hedge contracts have an automatic extension on the maturity date, however the currency hedge contracts are marked to market and settled daily and the date reflected herein is the next settlement date.

Currency Abbreviations

USD U.S. Dollar

GBP Pound Sterling

Shell plc ADRhedged™ Schedule of Investments

December 31, 2024

	<u>Shares</u>	<u>Value</u>
Common Stocks — 95.7%		
Energy — 95.7%		
Shell plc, ADR		
(Cost \$1,491,817).....	21,754	\$ 1,362,888
Short-Term Investment — 3.9%		
Money Market Funds — 3.9%		
Dreyfus Treasury Securities Cash Management Institutional Shares, 4.33% ^(a)		
(Cost \$55,356).....	55,356	55,356
Total Investments — 99.6%		
(Cost \$1,547,173)		1,418,244
Assets in excess of Other Liabilities, Net — 0.4%		5,731
Net Assets — 100%		<u>\$ 1,423,975</u>

(a) Reflects the 7-day yield at December 31, 2024.

ADR : American Depositary Receipt

PLC : Public Limited Company

At December 31, 2024, the Fund had the following currency swaps outstanding:

<u>Counterparty</u>	<u>Settlement Date*</u>	<u>Currency to Deliver</u>	<u>Currency to Receive</u>	<u>Unrealized Appreciation</u>	<u>Unrealized Depreciation</u>		
CIBC	01/02/25	USD	1,343,491	GBP	1,072,717	\$ —	\$ (26)
CIBC	01/02/25	GBP	1,072,717	USD	1,342,004	—	(1,461)
CIBC	01/03/25	GBP	1,073,132	USD	1,343,962	12	—
Total Unrealized Appreciation/(Depreciation)						<u>\$ 12</u>	<u>\$ (1,487)</u>

* The currency hedge contracts have an automatic extension on the maturity date, however the currency hedge contracts are marked to market and settled daily and the date reflected herein is the next settlement date.

Currency Abbreviations

USD U.S. Dollar

GBP Pound Sterling

Precidian ETFs Trust
Statements of Assets and Liabilities

December 31, 2024

	AstraZeneca PLC ADRhedged™	HSBC Holdings plc ADRhedged™	Shell plc ADRhedged™
Assets			
Investments, at fair value	\$ 1,664,910	\$ 1,675,637	\$ 1,418,244
Cash	8,865	8,688	7,216
Unrealized appreciation on currency swaps	14	14	12
Receivables:			
Dividends	445	245	220
Total assets	<u>1,674,234</u>	<u>1,684,584</u>	<u>1,425,692</u>
Liabilities			
Unrealized depreciation on currency swaps	1,810	1,781	1,487
Payables:			
Investment advisory fees	251	284	206
Accrued expenses and other liabilities	29	34	24
Total liabilities	<u>2,090</u>	<u>2,099</u>	<u>1,717</u>
Net Assets	<u>\$ 1,672,144</u>	<u>\$ 1,682,485</u>	<u>\$ 1,423,975</u>
Net Assets Consists of			
Paid-in capital	\$ 1,776,986	\$ 1,523,121	\$ 1,509,277
Distributable earnings (loss)	(104,842)	159,364	(85,302)
Net Assets	<u>\$ 1,672,144</u>	<u>\$ 1,682,485</u>	<u>\$ 1,423,975</u>
Number of Common Shares outstanding	<u>40,001</u>	<u>30,001</u>	<u>30,001</u>
Net Asset Value	<u>\$ 41.80</u>	<u>\$ 56.08</u>	<u>\$ 47.46</u>
Investments, at cost	<u>\$ 1,723,224</u>	<u>\$ 1,607,124</u>	<u>\$ 1,547,173</u>

Precidian ETFs Trust
Statements of Operations
For the Period Ended December 31, 2024

	AstraZeneca PLC ADRhedged™(1)	HSBC Holdings plc ADRhedged™(1)	Shell plc ADRhedged™(1)
Investment Income			
Dividend income	\$ 956	\$ 21,977	\$ 15,362
Interest income	2	2	3
Total income	<u>958</u>	<u>21,979</u>	<u>15,365</u>
Expenses			
Investment advisory fees	504	573	435
Miscellaneous fees	59	67	51
Total expenses	<u>563</u>	<u>640</u>	<u>486</u>
Net investment income	<u>395</u>	<u>21,339</u>	<u>14,879</u>
Net Realized and Unrealized Gain (Loss)			
Net realized gain (loss) from:			
In-kind redemptions	–	22,509	–
Currency swaps	63,436	71,833	56,469
Net realized gain	<u>63,436</u>	<u>94,342</u>	<u>56,469</u>
Net change in net unrealized appreciation (depreciation) on:			
Investments	(58,314)	68,513	(128,929)
Currency swaps	(1,796)	(1,767)	(1,475)
Net change in net unrealized appreciation (depreciation)	<u>(60,110)</u>	<u>66,746</u>	<u>(130,404)</u>
Net realized and unrealized gain (loss)	<u>3,326</u>	<u>161,088</u>	<u>(73,935)</u>
Net Increase (Decrease) in Net Assets Resulting from Operations	\$ 3,721	\$ 182,427	\$ (59,056)

(1) For the period October 4, 2024 (commencement of operations) through December 31, 2024.

Precidian ETFs Trust

Statements of Changes in Net Assets

	AstraZeneca PLC ADRhedged™ For the Period October 4, 2024 ⁽¹⁾ to December 31, 2024	HSBC Holdings plc ADRhedged™ For the Period October 4, 2024 ⁽¹⁾ to December 31, 2024	Shell plc ADRhedged™ For the Period October 4, 2024 ⁽¹⁾ to December 31, 2024
Increase (Decrease) in Net Assets from Operations			
Net investment income	\$ 395	\$ 21,339	\$ 14,879
Net realized gain	63,436	94,342	56,469
Net change in net unrealized appreciation (depreciation)	<u>(60,110)</u>	<u>66,746</u>	<u>(130,404)</u>
Net increase (decrease) in net assets resulting from operations	<u>3,721</u>	<u>182,427</u>	<u>(59,056)</u>
Distributions	<u>(108,563)</u>	<u>(23,063)</u>	<u>(26,246)</u>
Fund Shares Transactions			
Proceeds from shares sold	1,776,986	2,060,561	1,509,277
Value of shares redeemed	<u>—</u>	<u>(537,440)</u>	<u>—</u>
Net increase from capital share transactions	<u>1,776,986</u>	<u>1,523,121</u>	<u>1,509,277</u>
Total increase in net assets	<u>1,672,144</u>	<u>1,682,485</u>	<u>1,423,975</u>
Net Assets			
Beginning of period	<u>—</u>	<u>—</u>	<u>—</u>
End of period	<u>\$ 1,672,144</u>	<u>\$ 1,682,485</u>	<u>\$ 1,423,975</u>
Changes in Shares Outstanding			
Common Shares outstanding, beginning of period	—	—	—
Shares sold	40,001	40,001	30,001
Shares redeemed	<u>—</u>	<u>(10,000)</u>	<u>—</u>
Common Shares outstanding, end of period	<u>40,001</u>	<u>30,001</u>	<u>30,001</u>

(1) Commencement of operations.

Precidian ETFs Trust

Financial Highlights

AstraZeneca PLC ADRhedged™	Period Ended
Selected Per Share Data	December 31,
	2024^(a)
Net Asset Value, beginning of period	\$ 50.00
Income (loss) from investment operations:	
Net investment income ^(b)	0.01
Net realized and unrealized gain (loss) ^(c)	(5.50)
Total from investment operations	(5.49)
Less distributions from:	
Net investment income	(2.71)
Total distributions	(2.71)
Net Asset Value, end of period	\$ 41.80
Market price, end of period	\$ 42.06
Total Return based on Net Asset Value (%)	(10.96)^(d)
Total Return based on Market Price (%)	(10.41)^(d)
Ratios to Average Net Assets and Supplemental Data	
Net Assets, end of period (\$ millions)	\$2
Ratio of expenses (%)	0.19 ^(e)
Ratio of net investment income (loss) (%)	0.13 ^(e)
Portfolio turnover rate (%) ^(f)	0 ^(d)

(a) For the period October 4, 2024 (commencement of operations) through December 31, 2024.

(b) Per share numbers have been calculated using the average shares outstanding method.

(c) Because of the timing of subscriptions and redemptions in relation to fluctuating markets at value, the amount shown may not agree with the change in aggregate gains and losses.

(d) Not annualized.

(e) Annualized.

(f) Excludes the impact of in-kind transactions related to the processing of capital share transactions in Creation Units.

Precidian ETFs Trust

Financial Highlights (Continued)

HSBC Holdings plc ADRhedged™	Period Ended
Selected Per Share Data	December 31,
	2024^(a)
Net Asset Value, beginning of period	\$ 50.00
Income (loss) from investment operations:	
Net investment income ^(b)	0.78
Net realized and unrealized gain (loss)	5.88
Total from investment operations	<u>6.66</u>
Less distributions from:	
Net investment income	(0.58)
Total distributions	<u>(0.58)</u>
Net Asset Value, end of period	<u>\$ 56.08</u>
Market price, end of period	<u>\$ 56.36</u>
Total Return based on Net Asset Value (%)	13.35^(c)
Total Return based on Market Price (%)	13.91^(c)
Ratios to Average Net Assets and Supplemental Data	
Net Assets, end of period (\$ millions)	\$2
Ratio of expenses (%)	0.19 ^(d)
Ratio of net investment income (loss) (%)	6.33 ^(d)
Portfolio turnover rate (%) ^(e)	0 ^(c)
(a) For the period October 4, 2024 (commencement of operations) through December 31, 2024.	
(b) Per share numbers have been calculated using the average shares outstanding method.	
(c) Not annualized.	
(d) Annualized.	
(e) Excludes the impact of in-kind transactions related to the processing of capital share transactions in Creation Units.	

Precidian ETFs Trust

Financial Highlights (Continued)

Shell plc ADRhedged™ Selected Per Share Data	Period Ended December 31, 2024^(a)
Net Asset Value, beginning of period	\$ 50.00
Income (loss) from investment operations:	
Net investment income ^(b)	0.66
Net realized and unrealized gain (loss)	(2.33)
Total from investment operations	<u>(1.67)</u>
Less distributions from:	
Net investment income	(0.87)
Total distributions	<u>(0.87)</u>
Net Asset Value, end of period	<u>\$ 47.46</u>
Market price, end of period	<u>\$ 47.69</u>
Total Return based on Net Asset Value (%)	(3.29)^(c)
Total Return based on Market Price (%)	(2.82)^(c)
Ratios to Average Net Assets and Supplemental Data	
Net Assets, end of period (\$ millions)	\$1
Ratio of expenses (%)	0.19 ^(d)
Ratio of net investment income (loss) (%)	5.82 ^(d)
Portfolio turnover rate (%) ^(e)	0 ^(c)

(a) For the period October 4, 2024 (commencement of operations) through December 31, 2024.

(b) Per share numbers have been calculated using the average shares outstanding method.

(c) Not annualized.

(d) Annualized.

(e) Excludes the impact of in-kind transactions related to the processing of capital share transactions in Creation Units.

Precidian ETFs Trust

Notes to Financial Statements

December 31, 2024

1. Organization

Precidian ETFs Trust (the “Trust”) was organized as a Delaware statutory trust on August 27, 2010 as NEXT ETFs Trust and is authorized to have multiple segregated series or portfolios. The name of the Trust was changed on May 16, 2011 to Precidian ETFs Trust. The Trust is an open-end, management investment company registered under the Investment Company Act of 1940, as amended (“1940 Act”). As of December 31, 2024, the Trust currently consists of 3 investment portfolios, (each a “Fund” and collectively, the “Funds”) in operations and trading. These financial statements report on the Funds list below:

AstraZeneca PLC ADRhedged™

HSBC Holdings plc ADRhedged™

Shell plc ADRhedged™

The investment objective of the Funds is to provide investment results that generally correspond, before fees and expenses, to the total return of the ordinary shares of the non-U.S. company, as designated in such Fund name (each, an “Underlying Issuer,” and together, the “Underlying Issuers”), in its local market as traded in its local currency (“Local Currency”). There can be no assurance that a Fund’s objective will be achieved.

The Funds are classified as a non-diversified investment company under the Investment Company Act of 1940 (the “1940 Act”). A “non-diversified” classification means that the Fund is not limited by the 1940 Act with regard to the percentage of its assets that may be invested in the securities of a single issuer.

The Funds offer shares that are listed and traded on the Cboe BZX Exchange, Inc.

2. Significant Accounting Policies

The Funds are investment companies that apply the accounting and reporting guidance issued in Topic 946, “Financial Services-Investment Companies”, by the Financial Accounting Standards Board (“FASB”). The following is a summary of significant accounting policies consistently followed by the Funds. These policies are in conformity with generally accepted accounting principles (“GAAP”) in the United States of America.

(a) Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates and assumptions and such differences could be material.

(b) Investment Valuation

The Funds’ investments are valued daily at market value or, in the absence of market value with respect to any portfolio securities, at fair value. Market value prices represent readily available market quotations such as last sale or official closing prices from a national or foreign exchange (i.e., a regulated market) and are primarily obtained from third-party pricing services. If market quotations are not readily available, securities will be valued at their fair market value as determined in good faith under procedures approved by the Trust’s Board of Trustees (the “Board”). Although the Board is ultimately responsible for fair value determinations under Rule 2a-5 under the 1940 Act, the Board has delegated day-to-day responsibility for oversight of the valuation of the Funds’ assets to Precidian Funds LLC (the Manager) as the Valuation Designee pursuant to the Trust’s policies and procedures.

Equity securities are valued at the most recent sale price or official closing price reported on the exchange (U.S. or foreign) or over-the-counter market on which they trade. Securities or ETFs for which no sales are reported are valued at the calculated mean between the most recent bid and asked quotations on the relevant market or, if a mean cannot be determined, at the most recent bid quotation. Equity securities are generally categorized as Level 1 of the fair value hierarchy.

Money Market funds are valued at NAV and are categorized as Level 1.

Currency swap contracts will be valued using the prevailing exchange rate of the relevant non-U.S. currency at the time that NAV is calculated and are categorized as Level 2.

The Trust has adopted GAAP accounting principles related to fair value accounting standards which establish a definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value and a discussion of changes in valuation techniques and related inputs during the period. These inputs are summarized in the three broad levels listed below:

Level 1 – Quoted prices in active markets for identical assets that the Funds have the ability to access.

Precidian ETFs Trust

Notes to Financial Statements (Continued)

December 31, 2024

Level 2 – Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

Level 3 – Significant unobservable inputs (including the Funds' own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the valuations as of December 31, 2024 for the Funds based upon three levels defined above:

AstraZeneca PLC ADRhedged™

Assets	Level 1	Level 2	Level 3	Total
Common Stocks	\$ 1,615,265	\$ —	\$ —	\$ 1,615,265
Short-Term Investment	49,645	—	—	49,645
Total Investments in Securities	1,664,910	—	—	1,664,910
Other Financial Instruments:				
Currency Swaps	—	14	—	14
Total Investments in Securities and Other Financial Instruments	\$ 1,664,910	\$ 14	\$ —	\$ 1,664,924
Liabilities				
Other Financial Instruments:				
Currency Swaps	\$ —	\$ (1,810)	\$ —	\$ (1,810)
TOTAL	\$ 1,664,910	\$ (1,796)	\$ —	\$ 1,663,114

HSBC Holdings plc ADRhedged™

Assets	Level 1	Level 2	Level 3	Total
Common Stocks	\$ 1,613,583	\$ —	\$ —	\$ 1,613,583
Short-Term Investment	62,054	—	—	62,054
Total Investments in Securities	1,675,637	—	—	1,675,637
Other Financial Instruments:				
Currency Swaps	—	14	—	14
Total Investments in Securities and Other Financial Instruments	\$ 1,675,637	\$ 14	\$ —	\$ 1,675,651
Liabilities				
Other Financial Instruments:				
Currency Swaps	\$ —	\$ (1,781)	\$ —	\$ (1,781)
TOTAL	\$ 1,675,637	\$ (1,767)	\$ —	\$ 1,673,870

Shell plc ADRhedged™

Assets	Level 1	Level 2	Level 3	Total
Common Stocks	\$ 1,362,888	\$ —	\$ —	\$ 1,362,888
Short-Term Investment	55,356	—	—	55,356
Total Investments in Securities	1,418,244	—	—	1,418,244
Other Financial Instruments:				
Currency Swaps	—	12	—	12
Total Investments in Securities and Other Financial Instruments	\$ 1,418,244	\$ 12	\$ —	\$ 1,418,256
Liabilities				
Other Financial Instruments:				
Currency Swaps	\$ —	\$ (1,487)	\$ —	\$ (1,487)
TOTAL	\$ 1,418,244	\$ (1,475)	\$ —	\$ 1,416,769

Precidian ETFs Trust

Notes to Financial Statements (Continued)

December 31, 2024

(c) Fund Shares

The Funds issue and redeem their shares on a continuous basis, at NAV, only in blocks of 10,000 shares or whole multiples thereof ("Creation Units") to certain institutional investors (referred to as Authorized Participants) who have entered into agreements with the Funds' distributor. The Creation Units are issued and redeemed principally in-kind for portfolio securities (including any portion of such securities for which cash may be substituted) together with an amount of cash. Retail investors may purchase or sell shares only in the secondary market. Shares of the Funds trade at market price rather than NAV. As such, shares may trade at a price greater than NAV (premium) or less than NAV (discount).

The NAV per share of the Funds is determined as of the close of regular trading on the Cboe BZX Exchange, Inc, generally at 4:00 p.m. Eastern time. Any assets or liabilities denominated in currencies other than the U.S. dollar are typically translated into U.S. dollars at the close of regular trading on the NYSE, generally at 4:00 p.m. Eastern time, at then current exchange rates or at such other rates as deemed appropriate.

(d) Investment Transactions and Related Income

For financial reporting purposes, investment transactions are reported on the trade date. However, for daily NAV determination, portfolio securities transactions are reflected no later than in the first calculation on the first business day following trade date. Dividend income is recorded on the ex-dividend date. Interest income is recognized on an accrual basis and includes, where applicable, the amortization of premium or accretion of discount based on effective yield. Gains or losses realized on sales of securities are determined using the specific identification method by comparing the identified cost of the security lot sold with the net sales proceeds. Dividend income on the Statement of Operations is shown net of any foreign taxes withheld on income from foreign securities, if any, which are provided for in accordance with each Fund's understanding of the applicable tax rules and regulations.

(e) Foreign Currency Translation and Transactions

The accounting records of the Funds are maintained in U.S. dollars. Financial instruments and other assets and liabilities of the Funds denominated in a foreign currency, if any, are translated into U.S. dollars at current exchange rates. Purchases and sales of financial instruments, income receipts and expense payments are translated into U.S. dollars at the exchange rate on the date of the transaction. The Funds do not isolate that portion of the results of operations resulting from changes in foreign exchange rates from those resulting from changes in values to financial instruments. Such fluctuations are included with the net realized and unrealized gains or losses from investments. Realized foreign exchange gains or losses arise from transactions in financial instruments and foreign currencies, currency exchange fluctuations between the trade and settlement date of such transactions, and the difference between the amount of assets and liabilities recorded and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign exchange gains and losses arise from changes in the value of assets and liabilities, including financial instruments, resulting from changes in currency exchange rates. The Funds may be subject to foreign taxes related to foreign income received, capital gains on the sale of securities and certain foreign currency transactions (a portion of which may be reclaimable). All foreign taxes are recorded in accordance with the applicable regulations and rates that exist in the foreign jurisdictions in which the Funds invests.

(f) Federal Income Tax

Each Fund intends to continue to qualify as a "grantor trust" for U.S. federal income tax purposes. As a "grantor trust" for U.S. federal income tax purposes, the Funds will not pay U.S. federal income tax. Instead, the income and expenses of a Fund will be allocated on a pro rata basis to shareholders, and each Fund will report its income, gains, losses and deductions to the IRS and shareholders on that basis.

The grantor trust structure of the Funds is intended to be treated as a widely held fixed investment trust ("WHFIT") and should be subject to what is commonly referred to as the WHFIT Treasury Regulations. A WHFIT must satisfy certain detailed reporting requirements.

Management evaluates tax positions taken or expected to be taken in the course of its tax treatment, and its tax reporting to its shareholders, of these positions to determine whether the tax positions are "more-likely-than-not" to be sustained by the applicable tax authority. Tax positions not deemed to meet that threshold would be recorded as an expense in the current year. The Funds are required to analyze all open tax years. Open tax years are those years that are open for examination by the relevant income taxing authority. As of December 31, 2024, the Funds' 2024 tax returns are subject to audit by federal, state and local tax authorities.

Management of the Funds has evaluated whether or not there are uncertain tax positions that require financial statement recognition and has determined that no reserves for uncertain tax positions are required as of December 31, 2024.

(g) Distributions to Shareholders

The Funds typically earn income from ADR dividends, payments on the currency swap contracts, and from the money market investments, as well as proceeds from the sale of portfolio securities. All such income and proceeds will be deposited into the account used to settle the currency swap contracts ("Settlement Account"). Each shareholder will be allocated yearly its pro rata share of any income, gain, losses and deductions of the Funds as if the shareholder directly owned its pro rata share of the Funds' assets. Such income generally will be taxable to a shareholder regardless of whether it receives any cash distributions from the Funds or cash distributions that differ in amount from such income. The Funds taxable income will generally consist of ordinary income, capital gains or some combination of

Precidian ETFs Trust

Notes to Financial Statements (Continued)

December 31, 2024

both. To the extent a Fund has assets in its Settlement Account (Cash Component) in excess of 2% of the Funds' total assets on any quarterly distribution determination date, such Funds will distribute such excess pro rata to its shareholders. Such quarterly distribution determination date shall be on the last day of each calendar quarter (subject to the next business day in the case of a holiday or weekend) with payment occurring, if a payment is due, the next business day. Regarding the sale of portfolio securities, portfolio securities may be sold in such amounts only to cover then existing Funds' expenses and cash redemptions of shares, which such expenses shall be immediately paid after the sale of such portfolio securities.

(h) Indemnification

Under the Funds' organizational documents, the officers and Trustees are indemnified against certain liabilities arising out of the performance of their duties to the Funds. The Funds may enter into contracts that contain representations and that provide general indemnifications. The Funds' maximum liability exposure under these arrangements is unknown, as future claims that have not yet occurred may be made against the Funds.

3. Derivative Financial Instruments

In the normal course of business, the Funds use derivative contracts. Derivative contracts are subject to additional risks that can result in a loss of all or part of an investment. A Fund's derivative activities and exposure to derivative contracts are classified by the following primary underlying risks: interest rate, credit, foreign exchange, commodity price, and equity price. In addition to its primary underlying risks, the Funds are also subject to additional counterparty risk due to inability of its counterparties to meet the terms of their contracts.

FASB Accounting Standards Codification, Derivatives and Hedging ("ASC 815") requires enhanced disclosures about a Fund's use of, and accounting for, derivative instruments and the effect of derivative instruments on a Fund's financial position and results of operations. Tabular disclosure regarding derivative fair value and gain/loss by contract type (e.g., interest rate contracts, foreign exchange contracts, credit contracts, etc.) is required and derivatives accounted for as hedging instruments under ASC 815 must be disclosed separately from those that do not qualify for hedge accounting. Even though a Fund may use derivatives in an attempt to achieve an economic hedge, a Fund's derivatives are not accounted for as hedging instruments under ASC 815 because investment companies account for their derivatives at fair value and record any changes in fair value in current period earnings.

Currency Swaps Contracts

The Funds enter into currency swap transactions to hedge against fluctuations in the exchange rate between the U.S. dollar and the currency in which the securities of the Underlying Issuer is denominated. Such transactions are agreements between counterparties. A currency swap contract consists of an agreement between two parties to exchange cash flows on a notional amount of two or more currencies based on the relative value differential among them, such as exchanging a right to receive a payment in foreign currency for the right to receive U.S. dollars. Currency swap contracts may be entered into on a net basis or may involve the delivery of the entire principal value of one designated currency in exchange for the entire principal value of another designated currency. In such cases, the entire principal value of a currency swap is subject to the risk that the counterparty will default on its contractual delivery obligations.

The notional value of the currency swap contracts is adjusted daily based on the current fair value of the portfolio securities.

The currency swap contracts will be marked to market and settled daily based on the notional value of the currency swap contracts as of the settlement time on a particular day and the change in the value of the local currency in relation to the U.S. dollar from the settlement time on the prior business day to the settlement time on the current business day.

If as a result of a change in the value of the local currency relative to the U.S. dollar, the currency swap contracts increases in value, the counterparty will pay the Funds an amount in U.S. dollars equal to the increase in the value of the currency swap contracts. If the currency swap contracts decreases in value, the Funds will pay the counterparty an amount in U.S. dollars equal to the decrease in the value of the currency swap contracts. In order to obtain any necessary amount of cash, the Manager may sell portfolio securities. The Funds will maintain amounts not invested in ADRs in cash or cash equivalents, including money market funds.

Due to the unique nature of the Funds as a grantor trusts, certain aspects to the current hedging activities of the Funds' operations cannot be changed without adversely affecting the Funds' status as grantor trusts. As a result, certain service providers, such as a Fund trading counterparties, cannot be changed without affecting the Funds' tax status. Specifically, the Funds' counterparty for the currency swap contracts generally cannot be changed without affecting the Funds' tax status. The Manager will monitor the currency swap contracts to ensure the economics are reflective of market conditions.

Canadian Imperial Bank of Commerce will serve as the counterparty with the Funds in connection with the currency swap contracts. In order to maintain the Funds' status as grantor trusts, the Manager will not seek price quotes from other potential counterparties. As a result, the Funds may not always achieve the most favorable economics available in the market, although the Manager will monitor the currency swap contracts as described in the preceding paragraph.

Precidian ETFs Trust

Notes to Financial Statements (Continued)

December 31, 2024

The following table summarizes the value of the Funds' derivative instruments held as of December 31, 2024 and the related location in the accompanying Statement of Assets and Liabilities presented by underlying risk exposure:

		Asset Derivatives		Liability Derivatives	
AstraZeneca PLC ADRhedged™					
Currency Swaps - Foreign exchange contracts	Unrealized appreciation on currency swaps	\$	14	Unrealized depreciation on currency swaps	\$ 1,810
	Total	\$	14	Total	\$ 1,810

		Asset Derivatives		Liability Derivatives	
HSBC Holdings plc ADRhedged™					
Currency Swaps - Foreign exchange contracts	Unrealized appreciation on currency swaps	\$	14	Unrealized depreciation on currency swaps	\$ 1,781
	Total	\$	14	Total	\$ 1,781

		Asset Derivatives		Liability Derivatives	
Shell plc ADRhedged™					
Currency Swaps - Foreign exchange contracts	Unrealized appreciation on currency swaps	\$	12	Unrealized depreciation on currency swaps	\$ 1,487
	Total	\$	12	Total	\$ 1,487

For the period ended December 31, 2024, realized gains/(losses) and the change in unrealized appreciation/(depreciation) on currency swaps contracts by risk type, as disclosed in the Statements of Operations, are as follows:

	Currency Swaps — Foreign Exchange Contracts
Net Realized Gain (Loss) from:	
AstraZeneca PLC ADRhedged™	\$ 63,436
HSBC Holdings plc ADRhedged™	71,833
Shell plc ADRhedged™	56,469

	Currency Swaps — Foreign Exchange Contracts
Net Change in Unrealized Appreciation (Depreciation) on:	
AstraZeneca PLC ADRhedged™	\$ (1,796)
HSBC Holdings plc ADRhedged™	(1,767)
Shell plc ADRhedged™	(1,475)

The notional value of the currency swap contracts are adjusted daily based on the current fair value of the portfolio securities of the Funds. For the period ended December 31, 2024, the average of outstanding derivative financial instruments based on the the ending monthly contract values were as follows:

	Currency Swaps (Contract Value)
AstraZeneca PLC ADRhedged™	\$ (189)
HSBC Holdings plc ADRhedged™	(342)
Shell plc ADRhedged™	150

Precidian ETFs Trust

Notes to Financial Statements (Continued)

December 31, 2024

The Funds enter into International Swaps and Derivatives Association, Inc. Master Agreements (“ISDA Master Agreements”) or similar master agreements (collectively, “Master Agreements”) with its OTC derivative contract counterparties in order to, among other things, reduce its credit risk to counterparties. ISDA Master Agreements include provisions for general obligations, representations, collateral and events of default or termination. Under an ISDA Master Agreement, the Funds typically may offset with the counterparty certain derivative financial instrument’s payables and/or receivables with collateral held and/or posted and create one single net payment (close-out netting) in the event of default or termination.

The following table presents the Funds’ derivative assets and liabilities by counterparty net of amounts available for offset under a master netting agreement or similar arrangement (collectively referred to as “MNA”) and net of the related collateral received/pledged by the Funds as of December 31, 2024:

Fund	Gross Amounts of Assets Presented in the Statement of Assets and Liabilities (\$)	Financial Instruments and Derivatives Available for Offset (\$)	Collateral Received (\$)(a)	Net Amount of Derivative Assets (\$)	Gross Amounts of Liabilities Presented in the Statements of Assets and Liabilities (\$)	Financial Instruments and Derivatives Available for Offset (\$)	Collateral Pledged (\$)(a)	Net Amount of Derivatives Liabilities (\$)
AstraZeneca PLC ADRhedged™								
CIBC	14	(14)	—	—	1,810	(14)	—	1,796

Fund	Gross Amounts of Assets Presented in the Statement of Assets and Liabilities (\$)	Financial Instruments and Derivatives Available for Offset (\$)	Collateral Received (\$)(a)	Net Amount of Derivative Assets (\$)	Gross Amounts of Liabilities Presented in the Statements of Assets and Liabilities (\$)	Financial Instruments and Derivatives Available for Offset (\$)	Collateral Pledged (\$)(a)	Net Amount of Derivatives Liabilities (\$)
HSBC Holdings plc ADRhedged™								
CIBC	14	(14)	—	—	1,781	(14)	—	1,767

Fund	Gross Amounts of Assets Presented in the Statement of Assets and Liabilities (\$)	Financial Instruments and Derivatives Available for Offset (\$)	Collateral Received (\$)(a)	Net Amount of Derivative Assets (\$)	Gross Amounts of Liabilities Presented in the Statements of Assets and Liabilities (\$)	Financial Instruments and Derivatives Available for Offset (\$)	Collateral Pledged (\$)(a)	Net Amount of Derivatives Liabilities (\$)
Shell plc ADRhedged™								
CIBC	12	(12)	—	—	1,487	(12)	—	1,475

(a) The actual collateral received/(pledged) may be more than the amount shown.

Precidian ETFs Trust

Notes to Financial Statements (Continued)

December 31, 2024

4. Investment Advisory Fee and Other Transactions with Affiliates

(a) Investment Advisory and Administrative Services

Precidian Funds, LLC, a Delaware limited liability company, serves as investment manager to the Funds and has overall responsibility for the general management and administration of the Trust, pursuant to the Investment Management Agreement between the Trust and the Manager ("Management Agreement"). Under the Management Agreement, the Manager, subject to the supervision of the Board, provides an investment program for the Funds and is responsible for managing the investment of the Funds' assets in conformity with the stated investment policies of the Funds. The Manager is responsible for placing purchase and sale orders and providing continuous supervision of the investment portfolio of each of the Funds.

In addition to providing management services, under the Management Agreement, the Manager also: (i) supervises all non-management operations of the Funds; (ii) provides personnel to perform such executive, administrative and clerical services as are reasonably necessary to provide effective administration of the Funds; (iii) arranges for (a) the preparation of all required tax returns; (b) the preparation and submission of reports to existing Shareholders; (c) the periodic updating of prospectuses and statements of additional information; and (d) the preparation of reports to be filed with the SEC and other regulatory authorities; (iv) maintains the Funds' records; and (v) provides office space and all necessary office equipment and services.

The Management Agreement will remain in effect for an initial two-year term from commencement of operations and will continue in effect with respect to the Funds from year to year thereafter provided such continuance is specifically approved at least annually by: (i) the vote of a majority of the Funds outstanding voting securities or a majority of the Trustees of the Trust; and (ii) the vote of a majority of the Independent Trustees of the Trust, cast in person at a meeting called for the purpose of voting on such approval.

The Management Agreement will terminate automatically if assigned (as defined in the 1940 Act). The Management Agreement is also terminable at any time without penalty by the Trustees of the Trust or by vote of a majority of the outstanding voting securities of the Funds' on 60 days' written notice to the Manager or by the Manager on 60 days' written notice to the Trust. The Trust has entered into a licensing agreement with the Manager pursuant to which the Trust may use the terms "Precidian" and "ADRhedged™" without payment of a fee to the Manager under the agreement, provided that the Manager continues to be the Funds' investment manager pursuant to an investment management agreement with the Trust.

Pursuant to the Management Agreement the Manager, is entitled to receive a management fee of 0.17%, payable monthly and accrued daily, at the annual rate based on a percentage of the Funds' average daily net assets.

(b) Distribution Arrangement

The Funds have adopted a Distribution Plan (the "Distribution Plan") that allows the Funds to pay distribution fees to Foreside Fund Services, LLC (the "Distributor") and other firms that provide distribution services ("Service Providers"). Under the Distribution Plan, if a Service Provider provides distribution services, the Funds would pay distribution fees to the Distributor at an annual rate not to exceed 0.25% of average daily net assets, pursuant to Rule 12b-1 under the 1940 Act. The Distributor would, in turn, pay the Service Provider out of its fees. The Board currently has determined not to implement any 12b-1 fees pursuant to the Plan. 12b-1 fees may only be imposed after approval by the Board.

(c) Other Servicing Agreements

The Bank of New York Mellon, a wholly-owned subsidiary of The Bank of New York Mellon Corporation, serves as Co-Administrator, Custodian, Accounting Agent and Transfer Agent for the Funds.

Commonwealth Fund Services, LLC ("CFS") serves as co-administrator to the Trust and the Funds. CFS is responsible for providing certain administrative services to the Trust and the Funds, including coordination of meetings of the Board and services related thereto and the provision of certain Trust officers. CFS has also assumed the responsibility for, and it pays, all of the Funds' operating expenses other than the Funds' management fee, interest, distribution fees pursuant to Rule 12b-1 plans, taxes, acquired fund fees and expenses, brokerage commissions, dividend expenses on short sales, other expenditures which are capitalized in accordance with generally accepted accounting principles, and other extraordinary expenses not incurred in the ordinary course of business. For these services, CFS is paid 0.02% on the average daily net assets of the Funds, computed daily and paid monthly.

Foreside Financial Services, LLC (the "Distributor") serves as the distributor of Creation Units for the Funds on an agency basis. The Distributor does not maintain a secondary market in shares of the Funds.

(d) Trustees and Officers

Each Trustee who is not an "interested person" of the Trust receives compensation for their services to the Funds. Each Trustee receives an annual retainer fee, paid quarterly. Trustees are reimbursed for any out-of-pocket expenses incurred in connection with attendance at meetings. The Manager pays these costs.

Certain officers of the Trust are also officers and/or directors of CFS. Additionally, Practus, LLP serves as legal counsel to the Trust. John H. Lively, Secretary of the Trust, is Managing Partner of Practus, LLP. J. Stephen King, Jr., Assistant Secretary of the Trust, is a partner of

Precidian ETFs Trust

Notes to Financial Statements (Continued)

December 31, 2024

Practus, LLP. Neither the officers and/or directors of CFS, Mr. Lively or Mr. King receive any special compensation from the Trust or the Funds' for serving as officers of the Trust.

The Funds' Chief Compliance Officer and Assistant Chief Compliance Officer are not compensated directly by the Funds for their service. However, the Chief Compliance Officer is the Managing Member of Watermark Solutions, LLC ("Watermark"), which provides certain compliance services to the Funds, including the provision of the Chief Compliance Officer and the Assistant Chief Compliance Officer. The Assistant Chief Compliance Officer is the Managing Member of Fit Compliance, LLC, which has been retained by Watermark to provide the Assistant Chief Compliance Officer's services.

5. Investment Transactions

Purchases and sales of in-kind transactions for the period ended December 31, 2024 were as follows:

Fund	Purchases	Sales
AstraZeneca PLC ADRhedged™	\$ 1,673,578	\$ –
HSBC Holdings plc ADRhedged™	2,043,751	521,191
Shell plc ADRhedged™	1,491,817	–

6. Capital Share Transactions

The Funds issue and redeem their shares on a continuous basis, at NAV, only in blocks of 10,000 shares or whole multiples thereof ("Creation Units") to certain institutional investors (referred to as Authorized Participants) who have entered into agreements with the Funds' distributor. The Funds' Creation Units are issued and redeemed principally in-kind for portfolio securities (including any portion of such securities for which cash may be substituted) together with an amount of cash. Retail investors may purchase or sell shares only in the secondary market. Shares of the Funds trade at market price rather than NAV. As such, shares may trade at a price greater than NAV (premium) or less than NAV (discount).

The Funds issue and redeem shares only in bundles of a specified number of shares. These bundles are known as "Creation Units." For the Funds, a Creation Unit is comprised of 10,000 shares. To create or redeem a Creation Unit, you must be an "Authorized Participant" ("AP") or you must do so through a broker, dealer, bank or other entity that is an AP. An AP is either (1) a "Participating Party," (i.e., a broker-dealer or other participant in the clearing process of the Continuous Net Settlement System of the NSCC) ("Clearing Process") or (2) a participant of DTC ("DTC Participant"), and, in each case, must have executed an agreement with the Distributor with respect to creations and redemptions of Creation Units ("Participation Agreement"). All other persons or entities transacting in shares must do so in the Secondary Market. It is expected that only large institutional investors will create and redeem shares directly with a Fund in the form of Creation Units. In turn, it is expected that institutional investors who purchase Creation Units will break up their Creation Units and offer and sell individual shares in the Secondary Market.

Authorized Participants are charged standard creation and redemption transaction fees to offset transfer and other transaction costs associated with the issuance and redemption of Creation Units. The standard creation and redemption transaction fee is \$250. The standard creation transaction fee is charged to each purchaser on the day such purchaser creates a Creation Unit. The standard creation transaction fee is the same regardless of the number of Creation Units purchased by an investor on the same day. Similarly, the standard redemption transaction fee is the same regardless of the number of Creation Units redeemed on the same day. Authorized Participants who place creation orders through DTC for cash (when cash creations are available or specified) will also be responsible for the brokerage and other transaction costs of the Funds relating to the cash portion of such creation order. In addition, purchasers of shares in Creation Units are responsible for payment of the costs of transferring securities to the Funds and redeemers of shares in Creation Units are responsible for the costs of transferring securities from the Funds. Investors who use the services of a broker or other such intermediary may pay fees for such services.

7. Segment Reporting

In this reporting period, the Funds adopted FASB Accounting Standards Update 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures ("ASU 2023-07"). Adoption of the new standard impacted financial statement disclosures only and did not affect the Funds' financial position or the results of its operations. An operating segment is defined in Topic 280 as a component of a public entity that engages in business activities from which it may recognize revenues and incur expenses, has operating results that are regularly reviewed by the public entity's chief operating decision maker (CODM) to make decisions about resources to be allocated to the segment and assess its performance, and has discrete financial information available. The Principal Executive Officer (PEO) of the Funds, together with the Funds' portfolio management team act as the CODM. Since their commencement, the Funds operate as a single segment. The CODM monitors the operating results of the Funds, as a whole, and the Funds' long-term strategic asset allocation is pre-determined in accordance with the terms of its prospectus, based on a defined investment strategy which is executed by the Funds' portfolio managers as a team. The financial information, in the form of the Funds' portfolio composition, total returns, expense ratios and changes in net assets (i.e., changes in net assets resulting from operations, subscriptions and redemptions) are used by the CODM to assess the segment's performance versus the Funds' comparative benchmarks and to make resource allocation decisions for the Funds'

Precidian ETFs Trust

Notes to Financial Statements (Continued)

December 31, 2024

single segment, which is consistent with that presented within the Funds' financial statements. Segment assets are reflected on the accompanying Statements of Assets and Liabilities as "total assets" and significant segment expenses are listed on the accompanying Statements of Operations.

8. Subsequent Events

In preparing these financial statements, the Trust has evaluated events and transactions for potential recognition or disclosure through the date the financial were statements issued. The Trust has concluded that there are no subsequent events to note.

Precidian ETFs Trust

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Trustees:

Precidian ETFs Trust:

Opinion on the Financial Statements

We have audited the accompanying statements of assets and liabilities of Precidian ETFs Trust comprised of AstraZeneca PLC ADRhedged™, HSBC Holdings plc ADRhedged™ and Shell plc ADRhedged™ (each a Fund and collectively, the Funds), including the schedules of investments, as of December 31, 2024, the related statements of operations and changes in net assets for the period from October 4, 2024 (commencement of operations) through December 31, 2024, and the related notes (collectively, the financial statements) and the financial highlights for the period then ended. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Funds as of December 31, 2024, the results of their operations, changes in their net assets, and the financial highlights for the period from October 4, 2024 (commencement of operations) through December 31, 2024, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements and financial highlights are the responsibility of the Funds' management. Our responsibility is to express an opinion on these financial statements and financial highlights based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Funds in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial highlights. Such procedures also included confirmation of securities owned as of December 31, 2024, by correspondence with custodians and brokers or by other appropriate auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and financial highlights. We believe that our audits provide a reasonable basis for our opinion.

/s/ KPMG LLP

We have served as the Funds' auditor since 2024.

Columbus, Ohio

February 28, 2025

Precidian ETFs Trust Board Review of Investment Management Agreement (Unaudited)

At a meeting held on August 22, 2024 the “Meeting”, the Board of Trustees (the “Board”) of the Precidian ETFs Trust (the “Trust”) considered the approval of the proposed Investment Management Agreement (the “Management Agreement”) between the Trust and Precidian Funds, LLC (“Precidian,” or the “Manager”), with respect to the Series. The Board reflected on its discussions with the representatives from Precidian earlier in the Meeting regarding the manner in which the Series are to be managed and the roles and responsibilities of Precidian under the Management Agreement.

The Board reviewed a memorandum from counsel of the Trust (“Trust Counsel”) that addressed the Board’s duties when considering the approval of the Management Agreement and the responses of Precidian to requests for information from Trust Counsel on behalf of the Board. Trust Counsel noted that the response included information on the personnel of and services to be provided by Precidian, an expense comparison analysis for the Series and comparable ETFs, and the Management Agreement. He discussed the types of information and factors that should be considered by the Board in order to make an informed decision regarding the approval of the Management Agreement, including the following material factors: (i) the nature, extent, and quality of the services to be provided by Precidian; (ii) the investment performance of Precidian; (iii) the costs of the services to be provided and profits to be realized by Precidian from the relationship with the Series; (iv) the extent to which economies of scale would be realized if the Series grow and whether advisory fee levels reflect those economies of scale for the benefit of its investors; and (v) possible conflicts of interest and other benefits.

In assessing these factors and reaching its decisions, the Board took into consideration information specifically prepared or presented at this Meeting. The Board requested or was provided with information and reports relevant to the approval of the Management Agreement, including: (i) information regarding the services and support to be provided by Precidian to the Series and its shareholders; (ii) presentations by management of Precidian addressing the investment philosophy, investment strategy, personnel and operations to be utilized in managing the Series; (iii) information pertaining to the compliance structure of Precidian; (iv) disclosure information contained in the Series’ registration statement and the firm’s Form ADV and/or the policies and procedures of the firm; and (v) the memorandum from Trust Counsel that summarized the fiduciary duties and responsibilities of the Board in reviewing and approving the Management Agreement, including the material factors set forth above and the types of information included in each factor that should be considered by the Board in order to make an informed decision.

In assessing these factors and reaching its decisions, the Board took into consideration information specifically prepared or presented at this Meeting. The Board requested and received various informational materials including, without limitation: (i) documents containing information about Precidian, including financial information, personnel and the services to be provided by Precidian to the Series, the firm’s compliance program, current legal matters, and other general information; (ii) the advisory fee and projected annual operating expenses of the Series and comparative fee and expense information for other ETFs with strategies similar to the Series prepared by an independent third party; (iii) the anticipated effect of asset size on the Series’ overall expenses; and (iv) benefits anticipated to be realized by Precidian from its relationship with the Series, and certain conflicts of interest.

The Board did not identify any particular information that was most relevant to its consideration to approve the Management Agreement, and each Trustee may have afforded different weight to the various factors. In deciding whether to approve the Management Agreement, the Board considered the following factors:

The nature, extent, and quality of the services to be provided by Precidian.

In this regard, the Board considered the responsibilities of Precidian under the Management Agreement with the Trust. The Board reviewed the services to be provided by Precidian to the Series, including, without limitation, the processes of Precidian for assuring compliance with each Series’ investment objectives and limitations; Precidian’s intended processes for implementing the Series’ investment strategy, including the ability of Precidian to effect the foreign exchange swap aspect of the investment strategy of the Series in light of the each Series’ intended unique tax status as a grantor trust; the coordination of services by Precidian for the Series among the service providers; and the anticipated efforts of Precidian to promote the Series and grow its assets. The Board considered: the staffing, personnel, and methods of operating of Precidian; the education and experience of the firm’s personnel; and information provided regarding the firm’s compliance program and policies and procedures. After reviewing the foregoing and further information from Precidian, the Board concluded that the quality, extent, and nature of the services to be provided by Precidian, was satisfactory and adequate for the Series.

The investment performance of Precidian.

The Board noted that the Series had not yet commenced operations, and, as a result, they did not have any performance history. The Board also considered that Precidian is a newly registered adviser and does not have performance history with respect to other clients that have investment objectives similar to those of the Series.

The costs of services to be provided and profits to be realized by Precidian from the relationship with the Series.

In this regard, the Board considered the financial condition of Precidian and the level of commitment to the Series by Precidian. The Board also considered the projected assets and proposed expenses of the Series, including the nature and frequency of advisory payments. The Board noted the information on projected profitability provided by Precidian with respect to the management services provided to the Series. The Board considered the management fee proposed by Precidian for each Series. The Board compared the proposed management fee of each of the Series to the advisory fees and net expense ratios of ETFs from its Morningstar category (“Category”), and a peer group selected from its Category (“Peer Group”). The Board noted that the proposed management fee and projected net expense

Precidian ETFs Trust

Board Review of Investment Management Agreement (Unaudited) (Continued)

ratio for the Series were lower than the median advisory fees and median net expense ratio of the Series' Category and Peer Group. Each Series proposed advisory fee is 0.17% annually and each Series' total annual expense ratio is 0.19%. The Board acknowledged Precidian's representation that the Series will differ based on the underlying ADR and currency; however, they noted that the effort required to monitor and operate a Series is the same irrespective of a Series' asset size. The Board also noted that Precidian does not manage any separate accounts. After further consideration, the Board concluded that the projected profitability and fees to be paid to Precidian were within an acceptable range in light of the services to be rendered to the Series by Precidian.

The extent to which economies of scale would be realized as the Series grow and whether advisory fee levels reflect these economies of scale for the benefit of the Series' investors.

The Board considered that it was not anticipated that the Series would be of sufficient size to achieve economies of scale in the first few years of operations. The Board observed that Precidian does not have any direct arrangements in place to limit expenses of the Series and that its management fee did not have any breakpoints built into it. The Board noted that Precidian may consider such arrangements in the future depending on asset growth.

Possible conflicts of interest and other benefits.

In evaluating the possibility for conflicts of interest, the Board considered such matters as: the experience and ability of the advisory personnel assigned to the Series; the basis of decisions to buy or sell securities for the Series; and the substance and administration of the Code of Ethics and other relevant policies of Precidian. The Board also considered potential benefits for Precidian in managing the Series. The Board considered potential benefits to Precidian in light of a commercial arrangement it had entered into with an intended foreign exchange swap counterparty to the Series, and the Board considered the unique tax structure of each Series as a grantor trust and the limitations on Precidian to utilize a different swap counterparty. The Board noted that any potential conflicts of interest from the foregoing arrangements were adequately disclosed to them and appropriately balanced in light of all the surrounding circumstances, including without limitation the benefit afforded to the shareholders of the Series from the foreign exchange services. Following further consideration and discussion, the Board concluded that the standards and practices of Precidian relating to the identification and mitigation of potential conflicts of interest, as well as the benefits to be derived by Precidian from managing the Series were satisfactory.

The After additional consideration of the factors delineated in the memorandum provided by Trust Counsel and further discussion and careful review by the Board at the Meeting, the Board determined that the compensation payable under the Management Agreement was fair, reasonable and within a range of what could have been negotiated at arms-length in light of all the surrounding circumstances, and they approved the Management Agreement.

Investment Manager

Precidian Funds LLC
301 South State St.
Suite N-002
Newtown, PA 18940

Distributor

Forside Fund Services, LLC
Three Canal Plaza, Suite 100
Portland, ME 04101

Co-Administrator

Commonwealth Fund Services,
LLC
8730 Stoney Parkway
Suite 205
Richmond Virginia, 23235

**Independent Registered Public
Accounting Firm**

KPMG LLP
191 West Nationwide Blvd.
Suite 500
Columbus, Ohio 43215

**Custodian, Co-Administrator &
Transfer Agent**

The Bank of New York
240 Greenwich Street
New York, NY 10286

Legal Counsel

Practus LLP
11300 Tomahawk Creek Parkway
Suite 310
Leawood, Kansas 66211